Piper Jaffray analyst Edward Tenthoff said Novavax (NVAX) and Alnylam (ALNY) each have little to no European exposure and recommends buying their stocks on the weakness caused across markets by U.K voting to exit the European Union. The analyst, who has Overweight ratings on both stocks, noted that Novavax has Phase III RSV vaccine data due in the third quarter and Alnylam has two clinical data read-outs due in July.

The World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID-19 vaccine as one approach to address the ongoing SARS-CoV-2 virus evolution, which is expected to lead to circulation of additional JN.1 descendant strains, Novavax stated. Novavax plans to be ready to deliver our JN.1 protein-based non-mRNA COVID-19 vaccine globally this fall. We have been developing and manufacturing this vaccine candidate at risk and are well positioned for the upcoming vaccination season, the company said. Reference Link